Drug intelligence / Profile preview

(2Z)-N-biphenyl-4-yl-2-cyano-3-hydroxybut-2-enamide

Development stage
Unknown
Modality
Small Molecules
01

Overview

(2Z)-N-biphenyl–4–yl–2–cyano–3–hydroxybut–2–enamide is a synthetic small molecule belonging to the biphenyl derivatives class, with the molecular formula C17H14N2O2 and a molecular weight of approximately 278.31 g/mol. It is primarily referenced as an experimental compound in chemical and structural biology databases, including DrugBank (DB07443), PubChem (CID 54727972), and RCSB PDB ligand BCE[1][6][8]. The compound has not been approved for any therapeutic use or entered clinical trials beyond preclinical research phases. Its mechanism of action is not explicitly described in public sources; however, its code name "hDHODH-IN‑1" suggests it may act as an inhibitor of human dihydroorotate dehydrogenase (hDHODH), an enzyme involved in pyrimidine biosynthesis—a target relevant to immunomodulation and oncology research. No information on specific indications, developers, or manufacturers is available.

Other names
(Z)-2-cyano-3-hydroxy-N-(4-phenylphenyl)but-2-enamideN-{[1,1'-biphenyl]-4-yl}-2-cyano-3-hydroxybut-2-enamide1173715–42–8BCE
02

Targets

DHODH (Dihydroorotate dehydrogenase (quinone), mitochondrial)

Beyond the preview

Go deeper on (2Z)-N-biphenyl-4-yl-2-cyano-3-hydroxybut-2-enamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on (2Z)-N-biphenyl-4-yl-2-cyano-3-hydroxybut-2-enamide.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call